VEXUS and NGAL in the Diagnosis and Prognosis of Sepsis-associated Acute Kidney Injury
Comparison of Venous Excess Ultrasound Score (VExUS) With Neutrophil Gelatinase-associated Lipocalin (NGAL) in the Diagnosis and Prognosis of Sepsis-associated Acute Kidney Injury
1 other identifier
observational
100
0 countries
N/A
Brief Summary
In this prospective observational study, patients hospitalized in mixed intensive care unit, aged between 18 and 80, and diagnosed with sepsis and septic shock according to sepsis-3 criteria will be included. To determine whether patients develop AKI during the first five days of ICU admission, creatinine and urine output will be monitored daily for the first five days of ICU admission according to KDIGO criteria. Clinical diagnosis and treatment of AKI will be made according to KDIGO. According to KDIGO, patients will be divided into two groups: those who develop AKI and those who do not. By comparing plasma NGAL and VEXUS scores between groups, the sensitivity and specificity of the VEXUS score in determining AKI will be determined.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2024
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 5, 2024
CompletedFirst Posted
Study publicly available on registry
March 12, 2024
CompletedStudy Start
First participant enrolled
May 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 18, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 18, 2025
CompletedApril 23, 2024
April 1, 2024
11 months
March 5, 2024
April 22, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
ngal
neutrophil gelatinase-associated lipocalin
first and fifth days
VEXUS
venous excess ultrasound score (If VCI diameter is \< 2 cm, there is no congestion. If the VExUS score is 0, and you do not need to proceed further. If VCI\>2, congestion is present. Further examination is necessary to determine the severity of congestion and VExUS scores 1-3.Each of the hepatic, portal and renal veins are subsequently examined and classified as normal, mildly congested, or severely congested. The VExUS system has four grades: Grade 0 represents no congestion in any organ, Grade 1 represents only mild congestive findings, Grade 2 represents severe congestive findings in only one organ, and Grade 3 represents severe congestive findings in at least two out of three organ systems.
first and fifth days
Secondary Outcomes (1)
MORTALİTY
28 days
Study Arms (2)
1
Patients with sepsis who develop AKI
2
Patients with sepsis who not develop AKI
Interventions
Serum creatinine and urine amounts will be checked for five days.
Eligibility Criteria
sepsis and septic shock in ICU
You may qualify if:
- sepsis septic shock
You may not qualify if:
- Poor abdominal echogenicity,
- other conditions causing shock (hypovolemic, cardiogenic, neurogenic),
- life expectancy less than 24 hours, pregnancy, vasospastic disease, intraperitoneal pressure \> 15 mm Hg, obstructive renal failure liver and kidney transplanted patients, liver and kidney tumors, patients receiving dialysis treatment, single kidney and other kidney abnormalities, right heart failure, acute mesenteric ischemia chronic renal failure
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Inonu Universitylead
Biospecimen
blood sample for blood ngal level
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of Intensive Care Unit
Study Record Dates
First Submitted
March 5, 2024
First Posted
March 12, 2024
Study Start
May 1, 2024
Primary Completion
March 18, 2025
Study Completion
May 18, 2025
Last Updated
April 23, 2024
Record last verified: 2024-04